Abstract 118P
Background
Gastric cancer (GC) is a fourth leading cancer in Nepal and third most common cause for cancer-related mortality. This case-control study was carried out to find an association of behavioral and dietary factors in gastric cancer development among adult Nepali populations.
Methods
This study was conducted from Jan 2021 to Dec 2021 at Patan Academy of Health Sciences(PAHS), Lalitpur Nepal. In total, 89 patients with GC and 89 patients not having GC were studied as controls. Data were collected via face to face interview using a standard structured questionnaire, posing question about socio-demographic, behavioral and dietary habits, and clinical factors. Logistic regression method was used to calculate the odds ratio.
Results
The most common age group for both case and control was 55 to 65 years. The results showed that regular intake of red meat, duration of smoking, smokeless tobacco, fast food and fatty food, and family history of any type of cancer were directly associated with the risk of stomach cancer. On the contrary intake of chicken and vegetables, tea and coffee, regular walking and sports habit have inverse association with stomach cancer. Adjusted odds ratio shows, regular consumption of red meat have 2 times more risk (OR=2.0) of developing stomach cancer compare to irregular meat consumption. Moreover, person with history of H. pylori infection found 53% (OR=7.263; 95% CI; 3.614-14.597) more likely to develop stomach cancer.
Conclusions
Nepali studies on this topic are limited and more research is required to understand the etiology, need for development of suitable screening test, to demarcate high-risk population and to develop and evaluate the effect of primary prevention programs.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
79P - Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the phase III HIMALAYA study
Presenter: Arndt Vogel
Session: Poster viewing 02
82P - A randomized controlled, open-label, adaptive phase III clinical trial to evaluate safety and efficacy of EndoTAG-1 plus gemcitabine versus gemcitabine alone in patients with measurable locally advanced and/or metastatic adenocarcinoma of the pancreas after FOLFIRINOX
Presenter: Muh-Hwan Su
Session: Poster viewing 02
83P - Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
Presenter: Stephen Chan
Session: Poster viewing 02
84P - Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: A large real life worldwide population
Presenter: Margherita Rimini
Session: Poster viewing 02
86P - Outcomes by primary tumour location in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase III TOPAZ-1 study
Presenter: Aiwu Ruth He
Session: Poster viewing 02
87P - Socio-demographic disparities in esophageal cancer: A SEER analysis
Presenter: Beas Siromoni
Session: Poster viewing 02